1. Home
  2. SNDL vs GLSI Comparison

SNDL vs GLSI Comparison

Compare SNDL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SNDL Inc.

SNDL

SNDL Inc.

HOLD

Current Price

$1.43

Market Cap

381.0M

Sector

Health Care

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$27.63

Market Cap

327.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDL
GLSI
Founded
2006
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
381.0M
327.2M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SNDL
GLSI
Price
$1.43
$27.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$50.00
AVG Volume (30 Days)
2.8M
116.6K
Earning Date
04-29-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.19
N/A
Revenue Next Year
$3.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$7.78
52 Week High
$2.89
$34.10

Technical Indicators

Market Signals
Indicator
SNDL
GLSI
Relative Strength Index (RSI) 48.57 61.75
Support Level $1.31 $21.21
Resistance Level $1.63 $30.08
Average True Range (ATR) 0.06 1.76
MACD -0.00 0.49
Stochastic Oscillator 54.76 81.15

Price Performance

Historical Comparison
SNDL
GLSI

About SNDL SNDL Inc.

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: